<DOC>
	<DOCNO>NCT02362308</DOCNO>
	<brief_summary>The investigator test hypothesis endogenous aldosterone impairs insulin secretion insulin sensitivity subject primary aldosteronism .</brief_summary>
	<brief_title>Glucose Metabolism Subjects With Aldosterone-Producing Adenomas</brief_title>
	<detailed_description>The week study period , subject provide standard 160mmol/d sodium diet 6-8 day control inter-individual sodium intake . In period 1 , subject report 5 day control sodium diet hyperglycemic clamp study ( measure insulin secretion ) . Subjects continue study diet , return hyperinsulinemic-euglycemic clamp study ( measure insulin sensitivity ) . After completion period 1 assessment , subject undergo adrenalectomy endocrine surgeon initiate medical treatment , accord routine clinical care . In period 2 , investigator repeat study manner period 1 , 3 12 month adrenalectomy initiation medical treatment .</detailed_description>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Hyperaldosteronism</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>1 . Ambulatory subject , 18 70 year age , inclusive 2 . For female subject , follow condition must meet : postmenopausal status least 1 year , statuspost surgical sterilization , childbearing potential , utilization adequate birth control willingness undergo urine betahcg test every study day . 3 . Primary aldosteronism determine : Biochemical hyperaldosteronism define either : 1 . Plasma aldosterone ≥15 ng/dL 2. aldosteronetorenin ratio ≥30 ACE inhibitor 3. aldosteronetorenin ratio ≥40 absence ACE inhibitor Positive suppression test define either : 1. failure suppress aldosterone &lt; 7ng/dL intravenous 0.9 % saline infusion 2 hour 2. failure suppress 24hour urinary aldosterone excretion &lt; 12 µcg simultaneously document urine sodium excretion &gt; 200 mmol . Subjects present follow include study : 1 . Previously diagnose type 1 Diabetes 2 . Type II Diabetes , define ADA criterion : Hemoglobin A1C ≥6.5 % Fasting plasma glucose ≥126mg/dl ( 7.0mmol/l ) 2hour 75g oral glucose tolerance test ( OGTT ) plasma glucose ≥200mg/dl ( 11.1 mmol/l ) d. Current treatment antidiabetic medication ( ) 3 . Impaired renal function [ estimate glomerular filtration rate ( eGFR ) &lt; 30ml/min ] determine fourvariable Modification Diet Renal Disease ( MDRD ) equation , serum creatinine ( Scr ) express mg/dl age year . 4 . Prior allergy medication use study protocol ( e.g . Larginine , potassium chloride , insulin ) , drug within class . 5 . Screening plasma potassium &gt; 5.5 mmol/L sodium &lt; 135 mmol/L 6 . Cardiovascular disease recent ( &lt; 6 month ) myocardial infarction , presence angina pectoris , significant arrhythmia , congestive heart failure ( LV hypertrophy acceptable ) , deep vein thrombosis , pulmonary embolism , second third degree heart block , mitral valve stenosis , aortic stenosis hypertrophic cardiomyopathy 7 . Breastfeeding 8 . Treatment anticoagulants 9 . History serious neurologic disease cerebral hemorrhage , stroke , seizure , transient ischemic attack 10 . History presence immunological hematological disorder 11 . Diagnosis asthma require use inhale beta agonist &gt; 1 time per week 12 . Clinically significant gastrointestinal impairment could interfere drug absorption 13 . Impaired hepatic function [ aspartate amino transaminase ( AST ) and/or alanine amino transaminase ( ALT ) &gt; 2.0 x upper limit normal range ] 14 . Hematocrit &lt; 35 % 15 . Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult , arthritis treat nonsteroidal antiinflammatory drug 16 . Treatment chronic systemic glucocorticoid therapy ( 7 consecutive day 1 month ) 17 . Treatment lithium salt 18 . History alcohol drug abuse 19 . Treatment investigational drug 1 month precede study 20 . Mental condition render subject unable understand nature , scope possible consequence study 21 . Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>